| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44050523 | HTLV-1 | ENSG00000232810.5 | protein_coding | TNF | No | No | 7124 | P01375 Q5STB3 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | TNF |
|---|---|
| DrugBank ID | DB08904 |
| Drug Name | Certolizumab pegol |
| Target ID | BE0000704 |
| UniProt ID | P01375 |
| Regulation Type | neutralizer |
| PubMed IDs | 23620660; 28976302 |
| Citations | Chimenti MS, Saraceno R, Chiricozzi A, Giunta A, Chimenti S, Perricone R: Profile of certolizumab and its potential in the treatment of psoriatic arthritis. Drug Des Devel Ther. 2013 Apr 15;7:339-48. doi: 10.2147/DDDT.S31658. Print 2013.@@Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L: Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technol Assess. 2017 Oct;21(56):1-326. doi: 10.3310/hta21560. |
| Groups | Approved |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | PA165107055 |
| ChEMBL | CHEMBL1201831 |
